Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | F13A1 | P00488 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | TGM1 | P22735 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3214231 | 0.86 | HSD11B1 (1.00) | HSD11B1MEN1KMT2AF13A1TGM2 | |
| SCHEMBL3226058 | 0.86 | HSD11B1 (0.77) | HSD11B1MEN1KMT2AF13A1TGM2 | |
| SCHEMBL3221302 | 0.84 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL3222852 | 0.81 | HSD11B1 (0.74) | HSD11B1MEN1KMT2AF13A1TGM2 | |
| SCHEMBL2956786 | 0.81 | ALDH1A1 (0.61) | HSD11B1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL12577208 | 0.80 | HSD11B1 (0.64) | HSD11B1ALDH1A1F13A1TGM2TGM1 | |
| SCHEMBL10726996 | 0.80 | ALDH1A1 (0.86) | HSD11B1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL3212651 | 0.80 | HSD11B1 (0.67) | HSD11B1MEN1KMT2AALDH1A1F13A1 | |
| SCHEMBL3205601 | 0.79 | HSD11B1 (0.57) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2960456 | 0.78 | MEN1 (0.68) | MEN1KMT2AALDH1A1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1981848-A2 | 11-BETA HSD1 INHIBITORS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007092435-A2 | 11-BETA HSD1 INHIBITORS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885MEN1 1354/4885KMT2A 1609/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885MEN1 1687/4885KMT2A 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.